Literature DB >> 21594668

Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience.

Gianluca Rizzo1, Alessandro Armuzzi, Daniela Pugliese, Alessandro Verbo, Alfredo Papa, Claudio Mattana, Gian Lodovico Rapaccini, Luisa Guidi, Claudio Coco.   

Abstract

PURPOSE: The impact of preoperative use of TNF-alpha inhibitors on postoperative complications in patients with inflammatory bowel disease (IBD) undergoing abdominal surgery is controversial. The aim of this study was to evaluate the 30-day postoperative outcomes for IBD patients treated with these drugs prior to surgery.
METHODS: We analyzed retrospectively the incidence of short-term postoperative complications. Statistical analyses were performed to reveal the independent variables that influenced postoperative complications and the role of preoperative medical therapy with anti-TNF drugs within 12 weeks prior to surgery.
RESULTS: One hundred fourteen patients (76 with Crohn's disease (CD) and 38 ulcerative colitis (UC)) underwent abdominal surgery for IBD. Fifty-four patients were treated with anti-TNF-alpha within 12 weeks prior to surgery (anti-TNF group). Postoperative mortality and morbidity were 0% and 21%, respectively. The infection rate was 15%. A significantly higher incidence of postoperative complications was found in patients treated with high-dose steroids (58% vs. 17%; p = 0.003) after univariate analysis. The infection rate was significantly higher in patients treated with high-dose corticosteroids (50% vs. 11%; p = 0.002) and concomitant anti-TNF-alpha (60% vs. 13%; p = 0.023). Multivariate analysis revealed that only therapy with high-dose corticosteroids was significantly associated with cumulative (p = 0.017) and infective postoperative complications (p = 0.046). No significant differences were found between the anti-TNF group and the control group.
CONCLUSION: High-dose corticosteroids increased the risk of short-term postoperative cumulative and infective complications. Anti-TNF drugs within 12 weeks prior to abdominal surgery in patients with IBD did not appear to increase the rate of postoperative complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594668     DOI: 10.1007/s00384-011-1236-2

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  39 in total

1.  The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.

Authors:  L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171

2.  Surgery in patients on long-term steroid therapy: a tentative model for risk assessment.

Authors:  R Reding; L A Michel; J Donckier; L de Canniere; J Jamart
Journal:  Br J Surg       Date:  1990-10       Impact factor: 6.939

3.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

4.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

5.  Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.

Authors:  Z Yang; Q Wu; K Wu; D Fan
Journal:  Aliment Pharmacol Ther       Date:  2009-11-19       Impact factor: 8.171

Review 6.  Omission of temporary diversion in restorative proctocolectomy--is it safe?

Authors:  J J Tjandra; V W Fazio; J W Milsom; I C Lavery; J R Oakley; J M Fabre
Journal:  Dis Colon Rectum       Date:  1993-11       Impact factor: 4.585

7.  Factors affecting surgical risk in elderly patients with inflammatory bowel disease.

Authors:  Michael J Page; Lisa S Poritz; Susan J Kunselman; Walter A Koltun
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

8.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

9.  Risks of intestinal anastomoses in Crohn's disease.

Authors:  S Post; M Betzler; B von Ditfurth; G Schürmann; P Küppers; C Herfarth
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

10.  Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery.

Authors:  Liliana Bordeianou; Hiroko Kunitake; Paul Shellito; Richard Hodin
Journal:  Int J Colorectal Dis       Date:  2009-10-02       Impact factor: 2.571

View more
  16 in total

1.  Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease?

Authors:  Quinton M Hatch; Rubina Ratnaparkhi; Alison Althans; Michael Keating; Ruel Neupane; Madhuri Nishtala; Eric K Johnson; Scott R Steele
Journal:  J Gastrointest Surg       Date:  2016-09-15       Impact factor: 3.452

Review 2.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

3.  Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  YuJie Qiu; ZiCheng Zheng; Gang Liu; XinYu Zhao; AnQi He
Journal:  United European Gastroenterol J       Date:  2019-09-30       Impact factor: 4.623

4.  [Proctocolectomy in ulcerative colitis : is a multistep procedure in cases of immunosuppression advisable?].

Authors:  C Seifarth; J Gröne; N Slavova; B Siegmund; H J Buhr; J-P Ritz
Journal:  Chirurg       Date:  2013-09       Impact factor: 0.955

5.  Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Authors:  Chaya Shwaartz; Adam C Fields; Maximiliano Sobrero; Brian D Cohen; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2016-07-12       Impact factor: 3.452

6.  Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents.

Authors:  Tsuyoshi Hata; Tsunekazu Mizushima; Hideki Osawa; Hidekazu Takahashi; Naotsugu Haraguchi; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Masakazu Ikenaga; Kiyokazu Nakajima; Hirofumi Yamamoto; Kohei Murata; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2016-07-02       Impact factor: 2.549

Review 7.  Therapy of complicated Crohn's disease during pregnancy--an interdisciplinary challenge.

Authors:  C Seifarth; J P Ritz; U Pohlen; A J Kroesen; B Siegmund; B Frericks; H J Buhr
Journal:  Int J Colorectal Dis       Date:  2014-05-04       Impact factor: 2.571

Review 8.  Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?

Authors:  Gianluca Rizzo; Daniela Pugliese; Alessandro Armuzzi; Claudio Coco
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  The Impact of Preoperative Anti-TNFα Therapy on Postoperative Outcomes Following Ileocolectomy in Crohn's Disease.

Authors:  Afif N Kulaylat; Audrey S Kulaylat; Eric W Schaefer; Katelin Mirkin; Andrew Tinsley; Emmanuelle Williams; Walter A Koltun; Christopher S Hollenbeak; Evangelos Messaris
Journal:  J Gastrointest Surg       Date:  2020-01-21       Impact factor: 3.452

10.  Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis.

Authors:  Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2021-02-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.